“What we make here is cells.”

With crews still finishing electrical work and bulky lab equipment sitting ready for use, Dr. Jerome Ritz gave a tour this week of Dana-Farber Cancer Institute’s new, 30,000-square-foot cell manufacturing facility on the 12th floor of one of the hospital’s Boston buildings. It’s a factory of sorts, but one producing the potential medicines of the future, when treatments will be whipped up by editing DNA in cells that are then reintroduced into patients (some of these are already on the market) or even by converting one type of cell into another kind.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy